Fully human monoclonal antibody secreted by the E7.6.3 hybridoma; directed against human epidermal growth factor receptor (EGFr), a transmembrane cell-surface glycoprotein overexpressed in a variety of cancers. Prepn: A. Jakobovits et al., WO 9850433; eidem, US 6235883 (1998, 2001 both to Abgenix); and in vivo antitumor activity: X.-D. Yang et al., Cancer Res. 59, 1236 (1999) PubMed. Clinical pharmacokinetics: E. K. Rowinsky et al., J. Clin. Oncol. 22, 3003 (2004) DOI PubMed. Clinical trial in metastatic colorectal cancer: E. VanCustem et al., Ann. Oncol. 19, 92 (2008) DOI PubMed. Review of development and pharmacology: K. A. Foon et al., Int. J. Radiat. Oncol. Biol. Phys. 58, 984-990 (2004) DOI PubMed; of pharmacology and clinical experience with solid tumors: M. Wu et al., Clin. Ther. 30, 14-30 (2008) DOI PubMed.
Antineoplastic.
Antineoplastic; Monoclonal Antibodies